Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

WCLC 2018: NELSON – CT screening saves lives

Written by | 17 Oct 2018

A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer… read more.

WCLC 2018: Highlights

Written by | 17 Oct 2018

The IASLC 19th World Conference on Lung Cancer (WCLC) was full of highlights, including 3 plenary abstracts being presented in the New England Journal of Medicine and involvement from… read more.

ASCO 2018: Synchronous primary lung cancers

Written by | 20 Aug 2018

Professor John Lafrate (Harvard Medical School, Boston) and Professor Frank Detterbeck (Yale School of Medicine, New Haven) spoke in a session looking at some of the difficulties with diagnosis and… read more.

ASCO 2018: KEYNOTE-042 shows OS

Written by | 20 Aug 2018

First-line treatment with the PD-1 inhibitor pembrolizumab showed an overall survival benefit compared to platinum-based chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer and… read more.

ASCO 2018: Choices for front-line NSCLC

Written by | 20 Aug 2018

With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…

ASCO 2018: Hot topics in lung cancer

Written by | 20 Aug 2018

Hot topics in lung cancer – interviews from ASCO 2018.

ASCO Highlights

Written by | 20 Aug 2018

June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.

Cancer survival worse in RA patients

Written by | 19 Aug 2016

Survival was more than 2 years shorter in breast, prostate cancers.  Patients with rheumatoid arthritis (RA) had a 40% to 50% increased mortality risk if they developed breast… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year’s EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Written by | 2 Aug 2016

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year's EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Written by | 2 Aug 2016

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

ASCO 2016: Targeted therapy shows efficacy in advanced small cell lung cancer

Written by | 1 Jul 2016

by Bruce Sylvester: Investigative rovalpituzumab tesirine (Rova-T) appears to be safe and shows efficacy in treating advanced small cell lung cancer (SCLC), researchers reported in June, 2016 at… read more.

EMA Highlights: Green light for six new medicines

Written by | 28 Jun 2016

by Gary Finnegan: Six medicines, including two combination therapies for chronic hepatitis C, have been recommended for approval at the May meeting of the European Medicines Agency’s Committee for… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.